Good question, and I'd deal with the reaction before the timing. A local reaction that gets worse with every exposure means your immune system is learning the molecule. That is sensitization. Sermorelin, CJC, and tesamorelin are all built on the same GHRH 1-29 backbone. Reacting to all three and none of the GHRPs fits cross-reactivity to that shared sequence. There is one thing to rule out first: did all three come from the same source, or get mixed with the same bacteriostatic water? If so, the common thread could be an impurity or the diluent rather than the peptide itself. You can’t predict whether this ends in anaphylaxis. An escalating pattern is still one to stop rather than push through. Hives away from the injection site, lip or throat swelling, wheezing, or lightheadedness after a shot is an emergency. It may be worth asking your physician whether you should carry an epipen while you're still using peptides. I have one at home ever since I crashed in 25’…an ounce of prevention is worth a pound of cure. On IGF-1: for most adult men, 273 is not a deficiency number, though it depends on your age and the lab's range. I'd push back on picking 400 as the goal. Pick the thing you actually want to change, whether that's recovery, body comp, sleep, or joints, and make that the endpoint. Use IGF-1 as the safety check that tells you you're not overshooting. Sitting at the top of the range or above it long term is where the growth-signaling concerns live.For timing the "free pulse at night" probably won't work the way you're hoping. Exogenous GH raises IGF-1, and both GH and IGF-1 turn up somatostatin, which is the brake on your pituitary. Your own night pulse gets blunted whichever time you inject Ipamorelin at night would be pushing against that same brake. It also adds a second variable, so you won't know which one moved your glucose, appetite, or sleep.Between night and morning, the real tradeoff is glucose. GH drives fat breakdown, and the free fatty acids coming off that compete with glucose and create insulin resistance for several hours. At night that effect stacks on top of sleep and can show up as a higher fasting glucose the next morning. Morning fasted puts the fat breakdown in the window where you're already burning fat, and any glucose effect shows up during the day where you can see it and manage it. Bedtime dosing mimics your natural pulse better. With glucose as your main concern, I'd start morning fasted. I would change one thing at a time: GH alone, no IPA, for 4 to 6 weeks. Wear a CGM for the first two weeks if you can, because it will tell you far more than a single fasting draw. Recheck IGF-1 plus fasting glucose and insulin at 4 to 6 weeks. Early signs of too much are water retention, tingling or numbness in the hands, and joint aches.

Mike, that's really useful detail, and it tightens the picture a lot. Two compounding pharmacies plus an RUO source all giving you the same reaction makes contamination very unlikely. The stronger evidence is something you already tested without meaning to. Your GHRPs went through the same bac water and the same injection routine and never caused a problem. That takes the diluent off the table too. What's left is the molecule itself. One correction on my end. I said all three sit on the GHRH 1-29 backbone. Sermorelin and CJC are built on 1-29, but tesamorelin is the full 1-44 sequence with a small modification on the front end. The first 29 amino acids are still in there, so the shared-sequence explanation holds. I just want to be precise.The practical takeaway: treat anything built on GHRH as off the list for you. That includes Mod GRF 1-29, CJC with or without DAC, sermorelin, and tesamorelin, no matter who makes it or what it's labeled. One question that will help your doc: how soon after the shot does the reaction show up? An itchy, raised welt within minutes to an hour points toward an antibody-driven (IgE) reaction. That's the type that can escalate into something systemic. A firm red patch that builds over a day or two and peaks around day 2 or 3 fits a delayed, T-cell type reaction, which usually stays local. Both are reasons to stop. They just carry different risk, and your doc will want to know which one you've had. Photos with timestamps help a lot. Good call on the EpiPen conversation. GH itself is a different molecule, 191 amino acids with no GHRH sequence in it, so this history doesn't predict a reaction to it. Still, watch the site on your first few injections the same way. On the CGM, just confirm the Oura option is an actual sensor reading your glucose, not an estimate from the ring. On goals, you're right that 1.5 IU won't build much muscle on its own. At that dose GH is mostly doing two jobs: driving fat breakdown and supporting collagen in tendons, ligaments, and connective tissue. That second job is where a lot of the recovery benefit comes from. Muscle still comes from training and protein. GH makes the environment more supportive. One heads up. In the first few weeks, the scale and body comp scans can show a lean mass jump that's mostly water. Don't let that fool you in either direction.

Mike, your read is most of the way there. Carnitine behaves like a recycling system more than a fat burner, and that reframe does most of the work. It has two jobs. The famous one is the shuttle, long-chain fatty acids cannot cross the inner mitochondrial membrane on their own, so CPT1 swaps the CoA for carnitine, a translocase carries it across, and CPT2 swaps it back. That part is real and non-negotiable, and breaking any of those three steps is a genuine metabolic disease. But the shuttle is gated upstream by malonyl-CoA sitting on CPT1, so in a fed state fat transport is throttled no matter how much carnitine is standing around, which is why carnitine availability is almost never the rate-limiting step in a healthy, well-fed person. The second job matters more and gets discussed less. Cells have a finite pool of free coenzyme A, and when CoA is stuck holding acetyl and acyl groups the Krebs cycle jams, like a kitchen where every pan is dirty and nothing new can be cooked. Carnitine strips those groups off, forms acylcarnitines, and parks or exports them, keeping free CoA available. That is the recycle system you were describing, and it explains the entire pattern of who responds: carnitine helps when acyl groups are backing up, and does close to nothing when they are not. On Simon's TMAO concern, it is legitimate but it is context-dependent and usually attached to the wrong variable. You do not make TMAO. Gut bacteria convert unabsorbed carnitine to trimethylamine, your liver enzyme FMO3 oxidizes that to TMAO, and your kidney clears it, so three separate players are involved and only one of them cares what you swallowed. Oral supplements absorb at roughly 14 to 18 percent, so most of a gram never gets absorbed and arrives in the colon as bacterial substrate, which is where the whole TMAO story comes from. Injectable carnitine goes straight into plasma and never meets the colon, so that pathway is bypassed entirely, which answers Mike's question directly. And circulating TMAO is largely a kidney readout, freely filtered with fractional excretion near 100 percent of GFR, so it climbs as clearance falls. In an acute coronary syndrome cohort the TMAO-to-event association lost significance once kidney function was in the model, with eGFR mediating 58 percent of it, and carnitine itself showed no significant association with events. Saltwater fish and shellfish also deliver preformed TMAO that skips the microbes and the liver completely, so a tuna steak moves your number more than a carnitine capsule does, and nobody tells cardiology patients to stop eating fish. If TMAO worries you, the two variables worth knowing are your kidney function and who is living in your colon, the bottle is a distant third, and if you are injecting it is not a variable at all. The injectable specifics are where this gets concrete. Muscle carnitine uptake runs through a sodium-dependent transporter that is already saturated at normal plasma concentrations, a turnstile running at capacity, and pushing more people into the lobby does not make it spin faster. Five hours of IV infusion in healthy men, plasma carnitine driven to roughly ten times normal, and muscle carnitine content did not change at all. Repeat that infusion while clamping insulin at about 150 mIU/L and muscle total carnitine rises about 15 percent, with the threshold sitting somewhere above 50 mIU/L. So a 500 to 600 mg shot fasted before morning cardio raises plasma and extracellular carnitine sharply and the kidney clears most of it, while the muscle pool, the one that would actually change fat oxidation, barely moves. It still has a job, just a narrower one, as a plasma-compartment tool: acylcarnitine buffering, hepatic and renal handling, endothelial and red cell membrane exposure. Those are real compartments with real effects, they are simply not the compartment the marketing is selling. If you genuinely want to load muscle, the honest protocol is unglamorous, roughly 1.36 g of carnitine tartrate with about 80 g of carbohydrate twice daily for six months to raise the store about 20 percent, which sits awkwardly next to selling it as a fat-loss aid. For fat loss specifically, the supportive human data comes mostly from populations that were metabolically impaired to begin with, with pooled RCT work in type 2 diabetes showing around 2 g/day of oral carnitine reducing body mass and reaching most of its effect within about two weeks. That is the tell. It helps the person whose fat oxidation machinery is congested and does very little for the person whose machinery is clean and simply wants it to run faster, so I would consider it in the stalled dieter with a high acylcarnitine-to-free-carnitine ratio, the client grinding long low-intensity volume and clearing acyl traffic poorly, or the insulin-resistant client where mechanism and population evidence line up, and I would skip it as a fasted pre-cardio shot in someone who eats well and trains well. On performance there are two separate claims and they earn different verdicts. Loading does improve fuel selection and work capacity, shifting fat oxidation at low intensity, improving pyruvate dehydrogenase flux, lowering lactate at high intensity, and raising work output, but the entry fee is six months of daily carnitine plus a large daily carbohydrate load, which almost nobody does and almost nobody selling carnitine mentions. The recovery claim is the more defensible short-term one, with around 2 g/day of carnitine tartrate reducing markers of muscle damage and hypoxic stress after resistance training and increasing androgen receptor content in muscle, at doses and timeframes far too small to change muscle carnitine content, which tells me that effect is vascular and oxidative buffering, meaning better perfusion and less local hypoxia around the set, rather than fuel transport. Same molecule, different mechanism, which is why both claims can stand without contradicting each other. Where carnitine stops being optional is high-turnover terrain, and thalassemia is the clean example because it moves three variables at once. Turnover, because red cells are being destroyed continuously and a red cell constantly repairs its own membrane phospholipids, drawing down acyl supply every day. Loss, because iron overload and chelation therapy both stress the renal proximal tubule, which is exactly where filtered carnitine gets reabsorbed, so you have punched a hole in the bucket. Demand, because chronic anemia forces a high-output cardiac state and the heart is the most carnitine-dependent tissue in the body for fatty acid oxidation, so you have raised the rent on the tissue least able to skip a payment. Three deficits stacking is why measured carnitine deficiency in beta-thalassemia is a documented finding rather than a theory, and the trials line up with it: improved echocardiographic indices in beta-thalassemia major and intermedia including reduced left ventricular dilatation and hypertrophy, improved maximal oxygen consumption, cardiac output and oxygen pulse at peak exercise, a direct link between carnitine deficiency and red cell mechanical impairment, and in thalassemia minor patients on hemodialysis a roughly 39 percent reduction in erythropoietin requirement that reversed within weeks of stopping. Propionyl-carnitine specifically protects thalassemic erythrocytes from oxidative stress, which hints that form choice matters more there than it does in a healthy athlete. That setting is repletion of a measured deficit in someone who often has cardiac and renal involvement, so it belongs in a physician-led plan, and my job is spotting the pattern, bringing the literature, and making sure the hematologist and the cardiologist get asked the question. The same three-question check, turnover, loss, demand, applies to any carnitine-wasting picture: dialysis, valproate therapy, pivalate-conjugated antibiotics, ifosfamide, cyclosporine, or any proximal tubulopathy. The forms are also not interchangeable, and treating them as flavors of the same thing is where most of the money gets wasted. Think of the carnitine molecule as a delivery truck, where the attachment is both what is loaded in the back and where the truck is licensed to drive. Oral free carnitine absorbs at 14 to 18 percent, feeds your colonic bacteria with the rest, raises the systemic pool slowly, and carries the highest TMAO cost per unit of benefit. L-carnitine L-tartrate is chemically the same carnitine with a salt added for stability and dissolution, so it does not change gut fate and it does not change the TMAO question, and its real distinction is that it is the form used in most resistance-training recovery studies, so the recovery evidence sits with it by convention rather than chemistry, and at roughly 68 percent carnitine by weight 3 g of LCLT delivers about 2 g of carnitine, which people consistently miss when comparing doses across studies. Injectable levocarnitine gives essentially complete bioavailability with zero colonic exposure and no TMAO route, clears renally fast, fills the plasma and extracellular compartment, will not load muscle without concurrent insulin, and is an established therapy for primary and secondary carnitine deficiency and for dialysis patients, which tells you exactly which compartment it was designed to serve. Acetyl-L-carnitine crosses the blood-brain barrier far better and delivers an acetyl group into the acetyl-CoA and acetylcholine pools, making it the neural tool with its strongest human evidence in peripheral neuropathy and weaker mixed results in cognition and mood, so using it for fat loss is taking a brain-licensed truck to a warehouse job. Glycine propionyl-L-carnitine is worth flagging by name because people confuse it with alpha-GPC, which is a completely different compound, a choline donor, and choline is itself a TMA substrate, arguably a more efficient one than carnitine, so anyone making stack decisions on TMAO should be scrutinizing alpha-GPC harder than carnitine and almost nobody does. GPLC proper carries a propionyl group that converts to succinyl-CoA and enters the Krebs cycle directly, making it anaplerotic, so it refills the cycle instead of only shuttling fuel into it, and it holds the most substantial vascular literature of any carnitine form, particularly in peripheral arterial disease and claudication, with nitric oxide and blood flow effects. Simple mapping: oral carnitine or LCLT with carbohydrate over months if you are loading muscle, LCLT for training recovery and damage control, injectable levocarnitine for plasma buffering and clinical repletion, ALCAR for brain and nerve, GPLC or propionyl-L-carnitine for perfusion and ischemic tissue. On testing, labs confirm rather than diagnose, so I would not order a carnitine panel to decide whether carnitine is interesting, only when the result changes what I do, and two earn their place: free carnitine plus the acylcarnitine profile including the acyl-to-free ratio, where above roughly 0.25 suggests acyl groups are outrunning the buffer and there is genuinely something for carnitine to act on, and a cystatin C-based eGFR, which is there for the TMAO question rather than the carnitine one, because if clearance is intact that conversation is largely academic. Everything past those two is confirmatory. So where I land: overhyped as sold, yes, and as a fat burner in a healthy, replete athlete it is close to inert, with the fasted injectable version among the least mechanistically supported uses of anything in this industry. Underrated in specific terrain, also yes, because in hemolytic states, renal wasting, chelation, high-output cardiac demand, incomplete beta-oxidation and clinical deficiency it stops being a supplement and becomes repletion of something the body genuinely cannot keep up with. Your NAD+ comparison is apt with one refinement: both are cases where the mechanism is airtight and the supplementation logic does not automatically follow from it, but carnitine has something NAD+ precursors mostly lack, a real and measurable deficiency state with a real and measurable readout, which makes it far easier to be honest about, because you can find out whether the person needs it instead of arguing about whether they might. Find the terrain that makes the molecule necessary, or leave the molecule on the shelf.

@Mike Schultz you’ve got a really good handle on this stuff and you ask intelligent questions. Grateful to have you in the community and your questions make me think deeper so we’re both learning together.

Nate, I'd slow down before reaching for peptides, because the symptoms you're describing don't match the explanation you're working from. If 15 years of Adderall had left his dopamine system depleted, the picture you'd expect is flat, tired, unmotivated, sleeping a lot, and struggling to feel pleasure. That's what stimulant withdrawal usually looks like. Your friend has the opposite: palpitations, racing thoughts, and anxiety. That's a nervous system with too much arousal. The dopamine story may be part of it, but it doesn't explain what's in front of you, and if the hypothesis doesn't fit the symptoms, anything you pick to "reset dopamine" is aimed at the wrong target. That's the trap with the take-something-out, fill-the-gap approach. It assumes you know what the gap is. Adderall was doing a job for 15 years. Before you choose anything to add, you have to know what that job was, what's happening now that it's gone, and which of several possible explanations actually fits this person. There are a few different things that can look exactly like this. One is that whatever he was taking it for has come back. If he was diagnosed with ADHD, the racing thoughts may just be his baseline brain without the medication, and anxiety often rides along with unmanaged ADHD. Another is a nervous system that relied on an outside stimulant to regulate itself for 15 years and is now running on its own without the internal brakes fully back online. A third, and I see this a lot, is substitution: people coming off Adderall often lean harder on caffeine, pre-workout, or nicotine to get through the day, and that alone can produce palpitations and racing thoughts. A fourth is fuel. Adderall suppresses appetite, so after 15 years his eating pattern was probably built around not being hungry. If the new diet has him fasting, eating low carb, or under-eating while training hard, blood sugar dips will trigger adrenaline, and adrenaline feels exactly like anxiety with a pounding heart. The last is sleep. If his sleep is broken, everything above gets louder.

@Nathan Eckstein happy to help. Keep us posted on how they’re doing.

I've seen this exact pattern a lot late in an aggressive cut, so here's how I'd read it from the outside. You dropped 25 lb in 10 weeks, which is about 1.2% of your bodyweight a week, mostly very low carb, while lifting 5 days and running 3. Your body reads that as a lean season. When fuel runs short, the brain turns up the signals that keep an animal awake and foraging: adrenaline, cortisol, and orexin, which drives wakefulness when food is scarce. That's also why you feel sharp and the fog is gone. The great energy and the broken sleep are coming from the same place. The 2 to 3 a.m. wake-up has its own mechanism. Your liver stores sugar as glycogen to hold blood sugar steady overnight. After weeks of low carb and high training volume, that tank runs low in the early morning hours. When blood sugar dips, your body releases adrenaline and cortisol to bring it back up, and adrenaline at 2:30 a.m. wakes you up fully alert. Low carb also drains water and sodium, because glycogen holds water and low insulin makes your kidneys dump salt. Less fluid in the tank makes your nervous system run hotter to hold blood pressure, which adds to the same nighttime alertness. Your training time plays into it too. Bright light right after you get up at 4:15 pushes your body clock earlier, which means earlier sleepiness and earlier waking, the exact pattern you're stuck in. Wearing blue-light glasses from early evening then blocks the light that would push it back the other way. In the stack, SLU-PP-332 and 5-Amino-1MQ are both there to make you burn more, and your nervous system is already running hot. SLU-PP-332 also mimics the signal your runs already give you, so you're paying for the same effect twice while your sleep pays the bill. Tirzepatide keeps appetite and thirst down, which keeps the deficit deep. IGF-1 LR3 is the one I'd be most careful with right now. It lowers blood sugar the way insulin does, and on top of very low carb and a GLP-1, it raises the odds of the exact overnight dip that's waking you up. Starting SS-31, VIP, IGF-1 LR3 and enclomiphene all on the same day also means you can't read any of them. They didn't cause this, since your sleep broke 3 weeks ago, but if sleep gets better or worse now you won't know which one did it. And two of your worst nights were on DSIP, so you've already run that experiment.

Short version. Not overkill on AMPK, because they're arriving through different doors. The real issue is that one of them lowers ATP production while you're trying to build, and there's a human trial showing that exact mechanism blunting hypertrophy. Keep them apart in the day, keep the Complex I inhibitor away from training, and check whether you actually need the glucose disposal piece at all before you carry it through a whole growth phase.